Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer.

Abstract:

:Recurrent and second primary tumors arising within a previously radiated head and neck volume represent a difficult clinical scenario to manage. For patients who have resectable disease, surgery is the standard treatment. Chemotherapy is the standard for patients with unresectable or metastatic disease but offers no chance for cure. Re-irradiation (RRT) with concurrent chemotherapy is a potentially curative treatment option. In this article, we will review the basis for current chemoradiotherapy (CRT) regimens used in previously radiated patients, focusing on outcome and toxicity. Additionally, we will review radiotherapy techniques used in this setting and highlight the differences between definitive radiotherapy and RRT. Controversies, such as the utility of chemotherapy and RRT following surgical salvage, will be addressed. Finally, we will review investigations seeking to improve the therapeutic outcomes of patients treated with chemotherapy and RRT.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Salama JK,Vokes EE

doi

10.1053/j.seminoncol.2008.03.010

subject

Has Abstract

pub_date

2008-06-01 00:00:00

pages

251-61

issue

3

eissn

0093-7754

issn

1532-8708

pii

S0093-7754(08)00073-0

journal_volume

35

pub_type

杂志文章,评审
  • Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.

    abstract::A dose-finding study was set up to identify the optimal dose of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin for phase II studies in patients with advanced chemotherapy-naive non-small cell lung cancer (NSCLC). The influence of drug sequence on the toxicity and pha...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Giaccone G,Huizing M,Postmus PE,ten Bokkel Huinink WW,Koolen M,van Zandwijk N,Vermorken JB,Beijnen JH,Dalesio O,Pinedo HM

    更新日期:1995-08-01 00:00:00

  • Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.

    abstract::Non-platinum combination regimens have been developed for advanced non--small cell lung cancer using the novel and active agents docetaxel, gemcitabine, vinorelbine, and irinotecan. The aim of these combinations is to equal or exceed the survival benefits achieved with cisplatin doublets while minimizing toxicity. Of ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Rigas JR

    更新日期:2001-06-01 00:00:00

  • Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy.

    abstract::Hypoxic areas are a characteristic property of solid tumors. Hypoxia results from an imbalance between the supply and consumption of oxygen. Major pathogenetic mechanisms for the emergence of hypoxia are (1) structural and functional abnormalities in the tumor microvasculature; (2) an increase in diffusion distances; ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90210-6

    authors: Vaupel P,Kelleher DK,Höckel M

    更新日期:2001-04-01 00:00:00

  • Adjuvant therapy in rectal cancer: a protocol proposal.

    abstract::The use of adjuvant radiation therapy and chemotherapy diminishes the likelihood of local-regional and distant recurrences and appears to prolong survival in patients who have undergone a complete surgical resection of a Dukes-Kirklin stage B2 or C rectal cancer. Patients with this malignant condition rarely develop p...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Mayer RJ

    更新日期:1985-09-01 00:00:00

  • Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.

    abstract::Activation of mammalian target of rapamycin (mTOR) signaling occurs in a wide variety of human tumors and can lead to increased susceptibility to mTOR inhibitors. Temsirolimus, a novel analog of rapamycin, has shown promising preclinical and early clinical anti-tumor activity in various solid and hematologic tumor typ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2009.10.010

    authors: Dancey JE,Curiel R,Purvis J

    更新日期:2009-12-01 00:00:00

  • Prognostic factors in metastatic germ cell tumors.

    abstract::Metastatic germ cell cancer is a very heterogeneous group with respect to prognosis under cisplatinum-based chemotherapy. The main determinants of complete response and survival are not only the extension of the metastases but much more the biology of the underlying tumor which is represented by the location of the me...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Schmoll HJ,Beyer J

    更新日期:1998-04-01 00:00:00

  • Metabolic emergencies in the cancer patient.

    abstract::The acute tumor lysis syndrome (ATLS) is characterized by the rapid development of hyperuricemia, hyperkalemia, hyperphosphatemia, and acute renal failure (ARF). Hematologic malignancies are responsible for most cases of ATLS. Control of hyperuricemia and the achievement of a high urine flow are the mainstays of preve...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Flombaum CD

    更新日期:2000-06-01 00:00:00

  • Training and mentoring surgeons in lymphatic mapping.

    abstract::Intraoperative lymphatic mapping and selective lymphadenectomy for solid malignancies is a novel technique, having been introduced into surgical practice in the last 12 years. Dissemination of this technique among surgeons has followed a course similar to that found with the introduction of new laparoscopic techniques...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.03.005

    authors: Wilke LG

    更新日期:2004-06-01 00:00:00

  • The expanding role of cisplatin in the treatment of non-small-cell lung cancer.

    abstract::Cisplatin has been employed in the treatment of non-small-cell lung cancer (NSCLC) since the late 1970s. Current evidence suggests that it may be the most effective single drug for the treatment of NSCLC patients. The overall response rate as a single agent is 21%, though responses are higher in previously untreated p...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Bunn PA Jr

    更新日期:1989-08-01 00:00:00

  • Recent advances in pathologic evaluation and reporting of melanoma.

    abstract::Recent changes to the staging of melanoma, coupled with advances in surgical and medical treatment, have resulted in new methods for diagnostic evaluation and reporting of melanocytic lesions by pathologists. This review provides an update on recent changes in evaluation and reporting of primary melanoma, evaluation o...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.01.005

    authors: Mathew R,Messina JL

    更新日期:2012-04-01 00:00:00

  • The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis.

    abstract::Acquired immunodeficiency syndrome (AIDS)-related lymphomas consistently display a B-cell phenotype and are histogenetically related to germinal center (GC) or post-GC B cells in the overwhelming majority of cases. The pathogenesis of AIDS-related lymphoma is a multistep process involving factors provided by the host,...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Gaidano G,Capello D,Carbone A

    更新日期:2000-08-01 00:00:00

  • What is the optimal dose and duration of treatment with etoposide? I. Maximum tolerated duration of daily treatment with 50, 75, and 100 mg of oral etoposide.

    abstract::Because etoposide is a cell-cycle phase-specific drug, its degree of cytotoxicity likely relies on duration of cell exposure to a specific concentration. We investigated the maximum tolerated duration of oral etoposide treatment at doses of 100, 75, and 50 mg/d in previously treated patients with biopsy-proven, advanc...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Splinter TA,van der Gaast A,Kok TC

    更新日期:1992-12-01 00:00:00

  • CPT-11: clinical experience in phase I studies.

    abstract::Phase I studies of CPT-11 (irinotecan) have been conducted in Europe, the United States, and Japan to determine the maximum tolerated dose (MTD) and the most appropriate intravenous administration schedule for further evaluation in phase II investigations. Diarrhea and/or neutropenia were the major dose-limiting toxic...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Armand JP

    更新日期:1996-02-01 00:00:00

  • Mitoxantrone and cyclophosphamide in advanced breast cancer: a pilot study.

    abstract::A trial of combination chemotherapy using mitoxantrone-cyclophosphamide was started in 1983. Sixteen patients with widely metastatic cancer of the breast, including one man, received mitoxantrone, 10 mg/m2 intravenously (IV) over 30 minutes on day 1, followed by cyclophosphamide, 200 mg/m2 by mouth (PO) daily in divid...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: McDonald DB,Abu-Zahra H,Yoshida S,Binder H

    更新日期:1984-09-01 00:00:00

  • Gemcitabine combined with docetaxel in metastatic breast cancer.

    abstract::The combination of gemcitabine and docetaxel exhibits good activity in the treatment of advanced breast cancer. Phase II trial response rates using 21- or 28-day schedules have ranged from 36% to 79% in patient populations with varying degrees of pretreatment. In studies of extensively pretreated anthracycline-resista...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2003.37270

    authors: Fumoleau P

    更新日期:2003-04-01 00:00:00

  • The human interferon-alpha species and hybrid proteins.

    abstract::Ten years of interferon (IFN) therapy have followed the approval of this agent by the US Food and Drug Administration on June 5, 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the many new biotherapeutics. Regardless of this long history, however, we have just touched the surface of understand...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Pestka S

    更新日期:1997-06-01 00:00:00

  • Role of surgery in the treatment of bilio-pancreatic cancer: the European experience.

    abstract::Pancreatic cancer is the eighth most common cancer in Europe, accounting for 4.1% of cancer deaths in men and 4.8% in women. Standardized pancreatoduodenectomy and left pancreatectomy are the gold standard for routine surgical treatment of pancreatic cancer. Total pancreatectomy should be reserved for positive pancrea...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.37379

    authors: Pedrazzoli S,Pasquali C,Sperti C

    更新日期:2002-12-01 00:00:00

  • The use of chemotherapy as palliative treatment for patients with advanced ovarian cancer.

    abstract::Despite the high objective response rate of ovarian cancer to several reported platinum-based combination chemotherapy regimens, the majority of patients with advanced disease ultimately require consideration of a salvage regimen delivered for palliation of symptoms. A number of therapeutic strategies have been used i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Markman M

    更新日期:1995-04-01 00:00:00

  • Paclitaxel pharmacokinetics and pharmacodynamics.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the pla...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Kearns CM,Gianni L,Egorin MJ

    更新日期:1995-06-01 00:00:00

  • 3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.

    abstract::Early detection of response to neoadjuvant chemoradiation in esophageal cancer may allow individualization of treatment strategies and avoidance of unnecessary treatment. Although positron emission tomography (PET) with [(18)F]fluorodeoxyglucose (FDG) permits detection of changes in tumor proliferation before any chan...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2007.01.002

    authors: Chao KS

    更新日期:2007-04-01 00:00:00

  • Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma.

    abstract::Malignant biliary obstruction, duodenal, and gastric outlet obstruction, and tumor-related pain are the complications of unresectable pancreatic adenocarcinoma that most frequently require palliative intervention. Surgery involving biliary bypass with or without gastrojejunostomy was once the mainstay of treatment in ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.12.014

    authors: Stark A,Hines OJ

    更新日期:2015-02-01 00:00:00

  • Screening diagnosis and staging of esophageal cancer.

    abstract::In geographic areas where there is a high risk of esophageal cancer, analysis of cells obtained from the esophagus has been used effectively to detect early lesions. This has been demonstrated on a large scale in studies from China. Using abrasive balloon cytology techniques, 75% of the cancers detected were early les...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Lightdale CJ,Winawer SJ

    更新日期:1984-06-01 00:00:00

  • Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomas.

    abstract::The results of adjuvant chemotherapy in high-grade gliomas are disappointing. Carmustine (BCNU) wafers placed in the resection cavity provide a modest increase in median survival. However, the overall benefit of this approach is small, it offers no potential for cure, and the results are not statistically significant ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.035

    authors: Grossman SA

    更新日期:2003-12-01 00:00:00

  • Hepatic arterial chemotherapy in metastatic colorectal patients.

    abstract::Hepatic metastases are a major cause of morbidity and mortality for patients with colorectal cancer (CRC). The rationale for hepatic arterial chemotherapy has both an anatomical and pharmacological basis. Several randomized clinical studies of fluoropyrimidine showed higher response rates in all trials when the drug w...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Kemeny NE,Ron IG

    更新日期:1999-10-01 00:00:00

  • The association of malignancy with rheumatic and connective tissue diseases.

    abstract::This article reviews the associations of cancer with rheumatic diseases. Recent epidemiologic data linking the autoimmune connective tissue diseases with malignancy will be emphasized. Reports linking the occurrence of malignancy with rheumatoid arthritis, systemic lupus erythematosus, idiopathic inflammatory myopathy...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Carsons S

    更新日期:1997-06-01 00:00:00

  • Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?

    abstract::Human epidermal growth factor receptor-2 (HER2) is a member of the epidermal growth factor receptor family, which produces factors that are considered to be important mediators of cell growth. Overexpression of HER2, which occurs in approximately 25% to 30% of human breast cancers, has fostered considerable interest i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Ewer MS,Gibbs HR,Swafford J,Benjamin RS

    更新日期:1999-08-01 00:00:00

  • Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.

    abstract::The discovery that etoposide is one of the most active drugs in small-cell lung cancer (SCLC) led to its incorporation into a number of first-line combination chemotherapy regimens. The cyclophosphamide/doxorubicin/etoposide (CAE) regimen was shown to be as active or more active than other standard regimens in nonrand...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Bunn PA Jr,Greco FA,Einhorn L

    更新日期:1986-09-01 00:00:00

  • The role of bone marrow transplantation in the non-Hodgkin's lymphomas.

    abstract::In a significant fraction of patients with NHL, disease develops that is resistant to conventional chemotherapy. Experience using high-dose chemotherapy, with or without TBI, and BMT is expanding. Remissions can be achieved in many patients with refractory NHL in particular those patients with tumors that are still ch...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Williams SF

    更新日期:1990-02-01 00:00:00

  • Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.

    abstract::Docetaxel (Taxotere, Rhône-Poulenc Rorer, Antony, France) is highly effective in the first-line treatment of metastatic breast cancer, achieving an objective response rate of 61% (95% confidence interval, 52% to 69%). This rate of response is seen in patients with poor prognostic factors such as liver metastases and m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Trudeau ME

    更新日期:1999-06-01 00:00:00

  • Cellular immunotherapy and cancer.

    abstract::Recent data indicate that cellular immune responses can produce an anticancer effect. Two types of cellular immune responses appear to be clinically relevant: antigen specific immunity mediated by T cells that recognize tumor-associated peptide antigen expressed on surface HLA class I or class II molecules, and antige...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.02.021

    authors: Waller EK

    更新日期:2004-04-01 00:00:00